Killer – Zika Fever : Mosquito–borne virus is potential death sentence
THIS is the season of
fevers. The menace of fevers is rocking the world. True, yellow fever is no
longer a global threat, but malaria fever is still with us while typhoid fever
remains on the prowl. Sierra Leone is still at alert for Ebola fever and Saudi Arabia is
wary of the Middle East Respiratory Syndrome a.k.a MERS – a viral respiratory
illness that is relatively new to humans. Most people infected with MERS-CoV
developed severe acute respiratory illness, including fever, cough, and
shortness of breathe. It was first reported three years ago and the Saudi
government is “very keen” on finding a vaccine since there is pressing need to
control the spread of the MERS virus.zika The Lassa fever epidemic, currently
running around in Nigeria, also comes to mind. Nigerians are not at ease
because there is no vaccine against the disease at the moment; and no experimental
vaccine has completely protected non-human primates against a lethal challenge.
But right now, the world is not much bothered by MERS, Lassa fever or even
Ebola, The world’s latest health scare is a seemingly minor illness that
carries a killer wrapped inside – Zika, the mosquito-borne virus that is
sweeping across Latin America in the form of a tropical fever, linked to
neurological problems and a surge in microcephaly, a condition in which babies
are born with abnormally small heads. The defect can cause brain damage and
death. The outbreak of Zika virus has led authorities in some countries to urge
couples not to get pregnant, while the US Centers for Disease Control, CDC, has
warned pregnant women to avoid traveling to at least 25 affected countries. On
February 1, 2016, the World Health Organisation (WHO) declared Zika virus a
public health emergency of international concern. Following an Emergency
Committee Meeting on Zika virus, convened under the International Health
Regulations, 18 experts and advisers looked, in particular, at the strong
association, in time and place, between infection with the Zika virus and a
rise in detected cases of congenital malformations and neurological
complications. The experts agreed that a causal relationship between Zika
infection during pregnancy and microcephaly is strongly suspected, though not
yet scientifically proven, but all agreed on the urgent need to coordinate
international efforts to investigate and understand this relationship better.
The experts also considered patterns of recent spread and the broad
geographical distribution of mosquito species that can transmit the virus. The
lack of vaccines and rapid and reliable diagnostic tests, and the absence of
population immunity in newly affected countries were cited as further causes
for concern. After a review of the evidence, the Committee advised that the
recent cluster of microcephaly cases and other neurological disorders reported
in Brazil, following a
similar cluster in French Polynesia in 2014,
constituted an “extraordinary event” and a public health threat to other parts
of the world. Director General, WHO, Dr Margaret Chan, in a statement,
afterwards, said: “I am now declaring that the recent cluster of microcephaly
cases and other neurological disorders reported in Brazil,
following a similar cluster in French Polynesia
in 2014, constitutes a Public Health Emergency of International Concern. Chan
said a coordinated international response is needed to improve surveillance,
the detection of infections, congenital malformations, and neurological
complications, to intensify the control of mosquito populations, and to
expedite the development of diagnostic tests and vaccines to protect people at
risk, especially during pregnancy. Although the Committee found no public
health justification for restrictions on travel or trade to prevent the spread
of Zika virus, it noted that, at present, the most important protective
measures are the control of mosquito populations and the prevention of mosquito
bites in at-risk individuals, especially pregnant women. The virus What’s Zika?
This is probably the million-dollar question. Sunday Vanguard investigations
revealed that the virus was first identified in a rhesus monkey specie in Africa in 1947. WHO confirmed that Zika is actually named
after a forest in Uganda
where the first infected rhesus monkeys were found. The virus then “jumped”,
over time, to humans in Uganda
and Tanzania in East Africa. Hospital information says most of the time,
Zika disease infection goes unnoticed. The symptoms are like a mild case of the
flu — headache, muscle and joint pain, and mild fever — plus a rash and usually
last two to seven days. Zika is linked to two serious complications:
Neurological problems and birth defects in babies born to infected women. The
main neurological complication is Guillain-Barre syndrome, a disorder in which
the immune system attacks the nervous system, causing weakness and sometimes
paralysis. Most patients recover, but the syndrome is sometimes deadly. Cases linked
to Zika were first reported in Brazil
and French Polynesia. Microcephaly and other
brain deformities in newborns have also been reported, particularly in Brazil. Since
the Zika outbreak began, last year, microcephaly cases have surged. With no
vaccine, or specific treatment, Zika has become a potential death sentence
overnight. ‘No more pregnancy’ Recently, the US Centers for Diseases Control
issued a travel ban for pregnant women. Don’t travel to Brazil, it
warned. For women in Brazil,
Colombia, Ecuador, El
Salvador, Jamaica
and at least 18 other Latin America and Caribbean
countries, women have been advised to avoid pregnancy for the time being. An
American woman was reportedly said to have given birth to a baby with
microcephaly after traveling to Brazil.
The Zika virus itself is considered a bit of a dark horse by scientists. A
member of the flaviviridae family transmitted to humans by Aedes aegypti
mosquitoes, it is related to other pathogenic vector borne flaviviruses
including Dengue , West-Nile and Japanese encephalitis viruses but prior to the
last few months, produced a comparatively mild disease in humans. The vector
Like dengue fever and chikungunya, two similar diseases, Zika is transmitted by
the aedes mosquito species found in tropical and sub-tropical regions. The
specific host of the Zika virus is the aedes aegypti mosquito. It has a number
of aliases including the yellow fever mosquito, tiger mosquito or stegomyia
mosquito. The vector host is well distributed in Africa, the surrounding tropics
and subtropics, south eastern US, the Middle East, South East Asia, Pacific and
Indian Islands and Northern Australia. Sunday Vanguard gathered that the first
documented transmission of Zika virus, outside of its traditional endemic areas
in Africa and Asia,was recorded in 2007, when it caused an outbreak on the island of Yap in the Pacific. Today, Zika virus is
considered an emerging infectious disease with the potential to spread to new
areas where the aedes mosquito vector is present. However, there is still no
evidence of transmission Zika virus in Europe
to date and imported cases are rare. Entomological information provided by the
European Centres for Disease Control and Prevention, ECDCP, shows that the
aedes aegypti is a relatively small insect with an aggressive biting habit. It
is easily distinguished by its characteristic black and white pattern due to
the presence of white/silver scale patches on a black background on the legs
and other parts of the body. Aedes aegypti has a high biting and disease risk.
It is a known vector of several viruses including yellow fever virus, dengue
virus and chikungunya virus. Others are Japanese encephalitis, viral
haemorrhagic fevers and Zika virus. Over the past 25 years there has been an
increase in distribution of this mosquito to every continent worldwide making
it one of the most widespread mosquito species globally. The success of this
invasive species has largely been due to globalisation. It thrives in densely
populated areas which lack reliable water supplies, waste management and
sanitation. Historically, this mosquito has moved from continent to continent
via ships, and this method of dispersal is thought to present the highest risk.
It is even suggested that the mosquito evolved its domestic behaviour in West Africa and its widespread distribution and
colonisation in the tropics led to the highly efficient inter-human
transmission of viruses such as dengue. Sunday Vanguard investigations show
that aedes aegypti prefers mammalian hosts and will preferentially feed on
humans, even in the presence of alternative hosts. Historically, the
mosquitoesi were found in forested areas, using tree holes as aquatic habitats.
But as they have adapted to more urban domestic habitats, they have exploited a
wide range of artificial containers such as vases, water tanks and tyres that
are often associated with human habitations. The mosquito has also been found
utilising underground aquatic habitats such as septic tanks and adapting to use
both indoor and outdoor aquatic habitats in the same area. Adaptation to
breeding outdoors may allow for increased population numbers and difficulty in
implementation of control methods. The insect is often not found further than
100m from human habitations. They prefer human habitations that provide resting
and host-seeking possibilities and, as a result, will readily enter buildings.
Hope for a vaccine How far away is a Zika virus vaccine? Experts say research
efforts will focus on developing a vaccine for the mosquito-borne illness, but
it will take time. However, scientists have quickly turned their attention to
trying to develop a vaccine, but a widely available safe and effective Zika
vaccine is not likely this year and probably not in the next few years. Two
potential approaches have been mapped out to developing a Zika vaccine. The
first is a DNA-based strategy similar to one employed in a vaccine for West
Nile virus, in which a piece of the virus’s genetic structure is inserted into
another harmless virus and used to create an immune response in the patient.
The second, more traditional approach would use a live attenuated vaccine in
which the virus has been weakened to prompt immunity. Last week, Genekam, a
German biotechnology company, said it had created technology that can not only
reveal the presence of Zika pathogens in a blood sample, but also shed light on
the quantity in the patient’s blood. The new test can, therefore, definitely
determine if a person is a carrier of the Zika virus, as only one in five
people infected actually becomes ill, the media reports. Additionally, the test
renders diagnostic results in real time, which is relatively quick for a virus
of this kind. The test examines DNA and works with chemicals that react to the
Zika virus only. As the race to come up with a vaccine that could fight Zika
virus hots up, scientists admit that it’s not going to be easy. Scientists from
around the world have pledged to fast-track the research. U.S. National
Institutes of Health, Brazil’s
Butantan Institute and the Public Health Agency of Canada have already started
their research. Biotech firm, NewLink Genetics and Merck & Co, who are
behind the successful Ebola vaccine, are also working on a possible solution.
Large Pharmaceutical companies like Sanofi, GlaxoSmithKline and Japan’s Takeda
pharmaceutical are also in the race to develop the Zika virus vaccine. However,
despite technological advancements, scientists confessed that there are many
challenges to the development of a vaccine.The target profile is women who are
pregnant or who are planning to get pregnant – which is about the highest bar
there is for safety.
Check the Vanguard
newspaper for the full story.
Comments
Post a Comment